Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Christine Gruessner, Alessandra Brofferio, Emily Tomasulo, Jeanine Superata, Shellin Jose, Susan Soto, Said Hafizullah Fayaz, Christopher Pleyer, Pia Nierman, Ovsanna Melikyan, Adrian Wiestner, Mark Haigney, Clare Sun

Blood (2024) 144 (Supplement 1): 6787.

https://doi.org/10.1182/blood-2024-205119

Published: 2024

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Andy Itsara, Clare Sun, Inhye E. Ahn, Susan Soto, Douglas Rosing, Mark Haigney, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 4169–4170.

https://doi.org/10.1182/blood-2022-159716

Published: 2022

Journal Articles

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun

Blood (2021) 138 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2021-148539

Published: 2021

Journal Articles

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer, Mir A. Ali, Jeffrey I. Cohen, Xin Tian, Susan Soto, Inhye E. Ahn, Erika M. Gaglione, Pia Nierman, Gerald E. Marti, Charles Hesdorffer, Jennifer Lotter, Jeanine Superata, Adrian Wiestner, Clare Sun

Blood (2021) 137 (2): 185–189.

https://doi.org/10.1182/blood.2020008758

Published: 2021

Includes: Supplemental data

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Inhye E Ahn, MD, Yun-Ching Chen, PhD, Chingiz Underbayev, MD PhD, Erika M Gaglione, Clare Sun, MD, Susan Soto, Pia Nierman, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 850.

https://doi.org/10.1182/blood-2019-122142

Published: 2019

Journal Articles

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Inhye E. Ahn, Neil Basumallik, Xin Tian, Susan Soto, Adrian Wiestner

Blood (2019) 133 (22): 2452–2455.

https://doi.org/10.1182/blood.2019896688

Published: 2019

Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 186.

https://doi.org/10.1182/blood-2018-99-110326

Published: 2018

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Inhye E. Ahn, MD, Susan Soto, Pia Nierman, Xin Tian, PhD, Janet Valdez, Jennifer Lotter, Thomas Fleisher, Sergio Rosenzweig, Shakuntala Rampertaap, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 3020.

https://doi.org/10.1182/blood.V130.Suppl_1.3020.3020

Published: 2017

Journal Articles

High Prevalence of Multiple B Cell Clones in Patients with Chronic Lymphocytic Leukemia

Alankrita Taneja, MBBS, Clare Sun, MD, Constance Yuan, Maryalice Stetler-Stevenson, Susan Soto, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 1712.

https://doi.org/10.1182/blood.V130.Suppl_1.1712.1712

Published: 2017

Journal Articles

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Inhye E. Ahn, MD, Xin Tian, PhD, Jennifer Lotter, Susan Soto, Janet Valdez, Pia Nierman, Maryalice stetler-Stevenson, Constance Yuan, Irina Maric, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4302.

https://doi.org/10.1182/blood.V130.Suppl_1.4302.4302

Published: 2017

Journal Articles

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood (2017) 129 (11): 1469–1479.

https://doi.org/10.1182/blood-2016-06-719294

Published: 2017

Includes: Supplemental data

Journal Articles

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Inhye E Ahn, MD, Xin Tian, Susan Soto, Janet Valdez, Jennifer Lotter, Mohammed Farooqui, Adrian Wiestner, MD PhD

Blood (2016) 128 (22): 187.

https://doi.org/10.1182/blood.V128.22.187.187

Published: 2016

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Inhye Ahn, MD, Mohammed Farooqui, DO, Yuh Shan Lee, Gerald Marti, Susan Soto, RN, Xin Tian, PhD, Maryalice Stetler-Stevenson, Constance M. Yuan, MD PhD, Irina Maric, MD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 1750.

https://doi.org/10.1182/blood.V126.23.1750.1750

Published: 2015

Journal Articles

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Amanda Bray, RN, Xin Tian, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2933.

https://doi.org/10.1182/blood.V126.23.2933.2933

Published: 2015

NARROW

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

High Prevalence of Multiple B Cell Clones in Patients with Chronic Lymphocytic Leukemia

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only